Capital Research Global Investors
Institutional investor · Portfolio as of Q4 2018
Top Holdings417 positions
AbbVie Inc | 173.6M | $16B | 5.6% | $66.47 | 0.00% | 1 qtr | First report 0 |
Microsoft Corp | 109.9M | $11.2B | 3.9% | $94.43 | 0.00% | 1 qtr | First report 0 |
Facebook Inc | 69.8M | $9.1B | 3.2% | $129.85 | 0.00% | 1 qtr | First report 0 |
Abbott Laboratories | 121.9M | $8.8B | 3.1% | $62.83 | 0.00% | 1 qtr | First report 0 |
Amazon.com Inc | 4.7M | $7.1B | 2.5% | $75.10 | 0.00% | 1 qtr | First report 0 |
Netflix Inc | 25.7M | $6.9B | 2.4% | $26.77 | 0.00% | 1 qtr | First report 0 |
Amgen Inc | 35.1M | $6.8B | 2.4% | $153.91 | 0.00% | 1 qtr | First report 0 |
Broadcom Inc | 25.3M | $6.4B | 2.2% | $20.95 | 0.00% | 1 qtr | First report 0 |
Alphabet Inc | 5.1M | $5.3B | 1.8% | $51.29 | 0.00% | 1 qtr | First report 0 |
Verizon Communications Inc | 92.3M | $5.2B | 1.8% | $35.91 | 0.00% | 1 qtr | First report 0 |
Alphabet Inc | 4.8M | $5B | 1.8% | $51.76 | 0.00% | 1 qtr | First report 0 |
UnitedHealth Group Inc | 19.2M | $4.8B | 1.7% | $217.84 | 0.00% | 1 qtr | First report 0 |
Intel Corp | 97.6M | $4.6B | 1.6% | $40.39 | 0.00% | 1 qtr | First report 0 |
Gilead Sciences Inc | 72.5M | $4.5B | 1.6% | $46.93 | 0.00% | 1 qtr | First report 0 |
EOG Resources Inc | 45.7M | $4B | 1.4% | $64.11 | 0.00% | 1 qtr | First report 0 |
Exxon Mobil Corp | 55.4M | $3.8B | 1.3% | $48.91 | 0.00% | 1 qtr | First report 0 |
Philip Morris International In | 54.9M | $3.7B | 1.3% | $45.25 | 0.00% | 1 qtr | First report 0 |
Thermo Fisher Scientific Inc | 15.9M | $3.6B | 1.2% | $219.16 | 0.00% | 1 qtr | First report 0 |
General Dynamics Corp | 22.4M | $3.5B | 1.2% | $131.72 | 0.00% | 1 qtr | First report 0 |
NIKE Inc | 47.1M | $3.5B | 1.2% | $65.93 | 0.00% | 1 qtr | First report 0 |
Capital Research Global Investors manages $287B across 417 positions as of Q4 2018. Top holdings: ABBV (5.6%), MSFT (3.9%), META (3.2%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 4/5.0.
First quarter we have for this fund: 417 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $287.0B across 417 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR